Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.

Chéramy M, Hampe CS, Ludvigsson J, Casas R.

Clin Exp Immunol. 2013 Mar;171(3):247-54. doi: 10.1111/cei.12026.

2.

GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.

Skoglund C, Chéramy M, Casas R, Ludvigsson J, Hampe CS.

Pediatr Diabetes. 2012 May;13(3):244-50. doi: 10.1111/j.1399-5448.2011.00802.x. Epub 2011 Aug 16.

3.

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.

Chéramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R.

Clin Immunol. 2010 Oct;137(1):31-40. doi: 10.1016/j.clim.2010.06.001. Epub 2010 Jun 30.

PMID:
20580618
4.

Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.

Axelsson S, Chéramy M, Akerman L, Pihl M, Ludvigsson J, Casas R.

Diabetes Care. 2013 Nov;36(11):3418-24. doi: 10.2337/dc12-2251. Epub 2013 Jul 17.

5.

Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Hänninen A, Soilu-Hänninen M, Hampe CS, Deptula A, Geubtner K, Ilonen J, Knip M, Reijonen H.

Diabetes Metab Res Rev. 2010 May;26(4):271-9. doi: 10.1002/dmrr.1083.

6.

Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.

Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR.

J Autoimmun. 2011 Sep;37(2):79-87. doi: 10.1016/j.jaut.2011.05.005. Epub 2011 Jun 16. Review.

PMID:
21680149
7.

Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12.

Achenbach P, Hawa MI, Krause S, Lampasona V, Jerram ST, Williams AJK, Bonifacio E, Ziegler AG, Leslie RD; Action LADA consortium.

Diabetologia. 2018 Jul;61(7):1644-1649. doi: 10.1007/s00125-018-4605-3. Epub 2018 Apr 4.

8.

Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.

Chang T, Alexopoulos H, McMenamin M, Carvajal-González A, Alexander SK, Deacon R, Erdelyi F, Szabó G, Lang B, Blaes F, Brown P, Vincent A.

JAMA Neurol. 2013 Sep 1;70(9):1140-9. Erratum in: JAMA Neurol. 2014 Feb;71(2):244. Gabor, Szabó [corrected to Szabó, Gabor].

9.

GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.

Krause S, Landherr U, Agardh CD, Hausmann S, Link K, Hansen JM, Lynch KF, Powell M, Furmaniak J, Rees-Smith B, Bonifacio E, Ziegler AG, Lernmark A, Achenbach P.

Diabetes Care. 2014 Jun;37(6):1675-80. doi: 10.2337/dc13-1719. Epub 2014 Mar 5.

PMID:
24598244
10.

Humoral and cellular autoimmune responses in stiff person syndrome.

Lohmann T, Londei M, Hawa M, Leslie RD.

Ann N Y Acad Sci. 2003 Sep;998:215-22.

PMID:
14592879
11.

Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.

Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F.

Brain. 2008 Oct;131(Pt 10):2553-63. doi: 10.1093/brain/awn183. Epub 2008 Aug 7.

PMID:
18687732
12.
13.

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.

Axelsson S, Chéramy M, Hjorth M, Pihl M, Akerman L, Martinuzzi E, Mallone R, Ludvigsson J, Casas R.

PLoS One. 2011;6(12):e29008. doi: 10.1371/journal.pone.0029008. Epub 2011 Dec 12.

14.

Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.

Tavira B, Barcenilla H, Wahlberg J, Achenbach P, Ludvigsson J, Casas R.

J Diabetes Res. 2018 May 24;2018:9391845. doi: 10.1155/2018/9391845. eCollection 2018.

16.

Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.

Elding Larsson H, Lundgren M, Jonsdottir B, Cuthbertson D, Krischer J; DiAPREV-IT Study Group.

Pediatr Diabetes. 2018 May;19(3):410-419. doi: 10.1111/pedi.12611. Epub 2017 Nov 24.

PMID:
29171140
17.

Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.

Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, Scherbaum WA, Banga JP.

J Clin Endocrinol Metab. 1997 Aug;82(8):2664-70.

PMID:
9253351
18.

GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.

Liimatainen S, Honnorat J, Pittock SJ, McKeon A, Manto M, Radtke JR; T1D Exchange Biobank, Hampe CS.

Orphanet J Rare Dis. 2018 Apr 10;13(1):55. doi: 10.1186/s13023-018-0787-5.

19.

IgG1 is the dominant subclass of antibody against glutamic acid decarboxylase among type 1 diabetes in Japanese.

Kasuga A, Shimada A, Ozawa Y, Maruyama T, Oya K, Saruta T.

Endocr J. 2000 Feb;47(1):57-62.

20.

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD65-induced immune response.

Tavira B, Cheramy M, Axelsson S, Åkerman L, Ludvigsson J, Casas R.

Diabetologia. 2017 Jul;60(7):1276-1283. doi: 10.1007/s00125-017-4263-x. Epub 2017 Mar 29.

Supplemental Content

Support Center